13 results
P
patients with COPD
I/C
OM-85 BV, standard treatment
O
reduction in mean number of COPD exacerbations, days of antibiotic therapy
P
patients receiving chemotherapy or radiotherapy
I/C
prophylactic and therapeutic low-level laser therapy (LLLT), placebo or no therapy
O
severe oral mucositis (OM)
P
children (<18 years) with blunt pancreatic injuries
I/C
initially non-operative versus initially operative treatment, NOM vs. OM
O
non-operative management success rate, mortality, complications (including specifically pseudocysts and pancreatic fistulas), percent of patients and days on total parenteral nutrition (TPN), length of hospital stay, readmissions
P
early breast cancer patients
I/C
partial-breast irradiation (PBI), whole-breast radiotherapy (WBRT)
O
local recurrence (LR), overall mortality (OM), non-breast cancer mortality (NBCM)
P
Young dairy calves
I/C
Feeding milk replacer (MR) at 2 feeding rates, Moderate (MOD) vs. high (HI) feeding rates
O
Average daily gain (ADG), Gain/DMI, Hip width change, Starter intake, Apparent total-tract digestibility of DM, Organic matter (OM), CP, Neutral detergent fiber (NDF)
P
children with obstructive sleep apnea (OSA)
I/C
montelukast, placebo, routine drugs, single nasal spray of mometasone furoate
O
polysomnography (PSG) monitoring parameters, snoring and mouth breathing, adenoid morphology, sleep-disordered breathing (SDB)-related questionnaire scores, tonsil morphology
P
WHO, countries
I/C
AirQ+ software, 2021 guidelines for PM
O
number of avoidable annual deaths and associated economic benefits
P
people being investigated for tuberculosis
I/C
Xpert MTB/RIF, smear microscopy
O
mortality, proportion of participants starting tuberculosis treatment who had a successful treatment outcome, proportion of participants who were treated for tuberculosis, proportion of participants with bacteriological confirmation who were lost to follow-up pre-treatment, proportion of treated participants who had bacteriological confirmation
P
patients with COVID-19 and coronary heart disease
I/C
meta-analysis of literature concerning coronary heart disease and COVID-19, comparison of prognosis between patients with and without coronary heart disease
O
poor prognosis of COVID-19
P
people with non-exudative age-related macular degeneration (AMD)
I/C
photobiomodulation (PBM) therapy, standard care, sham treatment, or no treatment
O
best-corrected visual acuity (BCVA); contrast sensitivity; near vision; low luminance density score; reading speed; vision-related quality of life score; and adverse events such as progression of AMD and conversion to exudative AMD